Similar articles

• Acetylcysteine and renal function following coronary angiographic procedures.

  Bagshaw SM, Culleton BF. Bagshaw SM, et al. JAMA. 2003 Jun 4;289(21):2795; author reply 2796. doi: 10.1001/jama.289.21.2795-a. JAMA. 2003. PMID: 12783908 No abstract available.
• Acetylcysteine and renal function following coronary angiographic procedures.

  Balderramo DC. Balderramo DC. JAMA. 2003 Jun 4;289(21):2795-6; author reply 2796. doi: 10.1001/jama.289.21.2795-b. JAMA. 2003. PMID: 12783907 No abstract available.
• Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.

  Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Kay J, et al. JAMA. 2003 Feb 5;289(5):553-8. doi: 10.1001/jama.289.5.553. JAMA. 2003. PMID: 12578487 Clinical Trial.
• Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy.

  Anderson SM, Park ZH, Patel RV. Anderson SM, et al. Ann Pharmacother. 2011 Jan;45(1):101-7. doi: 10.1345/aph.1P275. Epub 2011 Jan 4. Ann Pharmacother. 2011. PMID: 21205947 Review.
• Nephrotoxicity of contrast media and protective effects of acetylcysteine.

  Briguori C, Quintavalle C, De Micco F, Condorelli G. Briguori C, et al. Arch Toxicol. 2011 Mar;85(3):165-73. doi: 10.1007/s00204-010-0626-5. Epub 2010 Dec 8. Arch Toxicol. 2011. PMID: 21140133 Review.